Elferink, R. Oude
May 2003
Gut;May2003 Supplement 2, Vol. 52, pIi42
Academic Journal
In contrast with urine formation, bile flow is not dependent on hydrostatic forces, but driven by osmotic pressure of solutes secreted across the apical membrane of hepatocytes and bile duct epithelial cells. This secretory process is mediated by a set of primary active transporters that use ATP hydrolysis to pump solutes against the concentration gradient. The most important solutes in bile are bile salts, lipids, electrolytes, and organic anions. The direct consequence of the osmotic mechanism of bile formation is that impaired function of these pumps leads to impaired bile flow—that is, cholestasis. The function of these pumps is highlighted by a number of inherited cholestatic diseases, which are caused by mutations in these genes. Identification of the molecular defect in these diseases was not only important for diagnostic reasons but also emphasized that impaired transporter function has pathological consequences. Indeed, it is now becoming clear that impaired or downregulated transporter function is also involved in the pathogenesis of acquired cholestatic syndromes.


Related Articles

  • Progressive Familial Intrahepatic Cholestasis. Srivastava, Anshu // Experimental & Clinical Hepatology;mar2014, Vol. 4 Issue 1, p25 

    Progressive familial intrahepatic cholestasis (PFIC) is a group of rare disorders which are caused by defect in bile secretion and presentwith intrahepatic cholestasis, usually in infancy and childhood. These are autosomal recessive in inheritance.The estimated incidence is about 1 per 50,000 to...

  • Cholestasis in patients with acquired immunodeficiency... Liu, Katherine J.M.; Atten, Mary Jo // American Surgeon;Jun1997, Vol. 63 Issue 6, p519 

    Reviews cholestasis in patients with acquired immunodeficiency syndrome (AIDS). Underlying causes of cholestasis; Predominant findings in patients with AIDS and hepatocellular diseases; Acalculous cholecystitis described; Two disease entities of abnormalities of intraheptic/extraheptic duct.

  • Everolimus.  // Reactions Weekly;6/19/2010, Issue 1306, p23 

    The article describes the cases of two patients who developed cholestasis after receiving everolimus.

  • Intrahepatic Cholestasis of Pregnancy (ICP) in U.S. Latinas and Chileans: Clinical features, Ancestry Analysis, and Admixture Mapping. Bull, Laura N.; Hu, Donglei; Shah, Sohela; Temple, Luisa; Silva, Karla; Huntsman, Scott; Melgar, Jennifer; Geiser, Mary T.; Sanford, Ukina; Ortiz, Juan A.; Lee, Richard H.; Kusanovic, Juan P.; Ziv, Elad; Vargas, Juan E. // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    In the Americas, women with Indigenous American ancestry are at increased risk of intrahepatic cholestasis of pregnancy (ICP), relative to women of other ethnicities. We hypothesized that ancestry-related genetic factors contribute to this increased risk. We collected clinical and laboratory...

  • Corrigendum.  // Journal of Clinical Investigation;Jul2004, Vol. 114 Issue 1, p142 

    Presents a correction to the article "Cathepsin B Inactivation Attenuates Hepatic Injury and Fibrosis During Cholestasis" that was previously published in the vol. 112, 2003 issue of the "Journal of Clinical Investigation."

  • Antidepressant induced cholestasis: hepatocellular redistribution of multidrug resistant protein (MRP2). Milkiewicz, P.; Chilton, A.P.; Hubscher, S.G.; Elias, E. // Gut;Feb2003, Vol. 52 Issue 2, p300 

    Background: We report two cases of antidepressant induced cholestasis. Case reports: We describe the first reported case of acute cholestasis due to citalopram (selective serotonin reuptake inhibitor) occurring in a patient who also experienced obstetric cholestasis in association with each of...

  • Hepatoprotection with tauroursodeoxycholate and β muricholate against tauroilthocolate induced cholestasis: involvement of signal transduction pathways. Milkiewicz, P.; Roma, M.G.; Elias, E.; Coleman, R. // Gut;Jul2002, Vol. 51 Issue 1, p113 

    Background: Tauroursodeoxycholate (TUDC) provides partial protection against taurolithocholate (TLC) induced cholestasis, possibly by inducing a signalling cascade activating protein kinase C (PKC). The potential protective effects of β muricholic acid (β-MC), another 7-β-hydroxylated...

  • Arteriohepatic Dysplasia: A Benign Syndrome of Intrahepatic Cholestasis with Multiple Organ Involvement. Riely, Carolyn A.; Cotlier, Edward; Jensen, Pamela S.; Klatskin, Gerald // Annals of Internal Medicine;Oct79, Vol. 91 Issue 4, p520 

    Presents clinical reports of patients with arteriohepatic dysplasia or Alagille's syndrome, an intrahepatic cholestatic syndrome. Information on intrahepatic cholestasis; Background on the patients; Results of the clinical reports.

  • Sepsis and cholestasis. Paton, Alex // British Medical Journal (Clinical Research Edition);10/6/1984, Vol. 289 Issue 6449, p857 

    Examines the association of cholestasis with sepsis. Cause of cholestasis; Symptoms on the development of sepsis in patients with cholestasis; Sites common in sepsis infection.


Read the Article


Sign out of this library

Other Topics